表紙
市場調查報告書

人工胰臟:開發中產品分析

Artificial Pancreas - Medical Devices Pipeline Assessment, 2019

出版商 GlobalData 商品編碼 334921
出版日期 內容資訊 英文 151 Pages
訂單完成後即時交付
價格
Back to Top
人工胰臟:開發中產品分析 Artificial Pancreas - Medical Devices Pipeline Assessment, 2019
出版日期: 2019年07月05日內容資訊: 英文 151 Pages
簡介

本報告提供目前開發中的人工胰臟的開發中產品資訊調查分析,提供您主要產品·計劃,主要企業,臨床實驗資訊,最近的趨勢等相關的系統性資訊。

第1章 目錄

第2章 簡介

  • 人工胰臟概要

第3章 開發中的產品

  • 人工胰臟 - 開發中產品:各開發階段
  • 人工胰臟 - 開發中產品:各地區
  • 人工胰臟 - 開發中產品:各法規途徑
  • 人工胰臟 - 開發中產品:各核準時期 (預定)
  • 人工胰臟 - 進行中的臨床實驗

第4章 人工胰臟:正在開發的開發中產品 (各企業)

  • 人工胰臟企業 - 開發中產品:各開發階段
  • 人工胰臟 - 開發中產品:各開發階段

第5章 人工胰臟企業與產品概要

  • Advanced Biosensors-Ohio, Llc
  • Animas Corporation
  • Beta-O2 Technologies Ltd.
  • Bigfoot Biomedical, Inc.
  • BioTex, Inc.
  • Boston University
  • Cerco Medical
  • Converge Biotech, Inc.
  • Covalor Medical, LLC
  • De Montfort University
  • Defymed
  • Diabeloop
  • Dose Safety Inc.
  • Imperial College London
  • Inreda Diabetic BV
  • Kencak LLC
  • Medtronic plc
  • Miromatrix Medical Inc.
  • Pacific Diabetes Technologies, Inc.
  • Pancreum, LLC
  • PharmaCyte Biotech, Inc.
  • Rensselaer Polytechnic Institute
  • Schneider Children's Medical Center of Israel
  • TecMed, Inc.
  • The University of Newcastle
  • Ultradian Diagnostics LLC
  • Universidad Autonoma de Madrid
  • Universitat Politecnica de Valencia
  • University of California, San Francisco
  • University of California, Santa Barbara
  • University of Cambridge
  • University of Florida
  • University of Virginia
  • ViaCyte, Inc.
  • XERIS Pharmaceuticals, Inc.

第6章 人工胰臟:最近的趨勢

第7章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0785EPD

GlobalData's Medical Devices sector report, "Artificial Pancreas - Medical Devices Pipeline Assessment, 2019" provides an overview of Artificial Pancreas currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Artificial Pancreas pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Artificial Pancreas under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Artificial Pancreas and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Artificial Pancreas under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date.

Table of Contents

1 Table of Contents

  • 1.1 List of Table
  • 1.2 List of Figures

2 Introduction

  • 2.1 Artificial Pancreas Overview

3 Products under Development

  • 3.1 Artificial Pancreas - Pipeline Products by Stage of Development
  • 3.2 Artificial Pancreas - Pipeline Products by Territory
  • 3.3 Artificial Pancreas - Pipeline Products by Regulatory Path
  • 3.4 Artificial Pancreas - Pipeline Products by Estimated Approval Date
  • 3.5 Artificial Pancreas - Ongoing Clinical Trials

4 Artificial Pancreas - Pipeline Products under Development by Companies

  • 4.1 Artificial Pancreas Companies - Pipeline Products by Stage of Development
  • 4.2 Artificial Pancreas - Pipeline Products by Stage of Development

5 Artificial Pancreas Companies and Product Overview

  • 5.1 Admetsys Corp Company Overview
  • 5.2 Advanced Biosensors-Ohio LLC (Inactive) Company Overview
  • 5.3 Beta Bionics Inc Company Overview
  • 5.4 Beta-O2 Technologies Ltd Company Overview
  • 5.5 Bigfoot Biomedical Inc Company Overview
  • 5.6 BioTex Inc Company Overview
  • 5.7 Cerco Medical LLC Company Overview
  • 5.8 Converge Biotech, Inc. Company Overview
  • 5.9 Covalor Medical, LLC Company Overview
  • 5.10 De Montfort University Company Overview
  • 5.11 Debiotech SA Company Overview
  • 5.12 Defymed SAS Company Overview
  • 5.13 Diabeloop Company Overview
  • 5.14 EOFlow Co Ltd Company Overview
  • 5.15 Giner Inc Company Overview
  • 5.16 Harvard John A Paulson School of Engineering and Applied Sciences Company Overview
  • 5.17 Healios Inc Company Overview
  • 5.18 Imperial College London Company Overview
  • 5.19 Inreda Diabetic BV Company Overview
  • 5.20 Insulet Corp Company Overview
  • 5.21 Kencak LLC Company Overview
  • 5.22 Medicsensors SL Company Overview
  • 5.23 Medtronic Diabetes Company Overview
  • 5.24 Miromatrix Medical Inc Company Overview
  • 5.25 Pacific Diabetes Technologies, Inc. Company Overview
  • 5.26 Pancreum, LLC Company Overview
  • 5.27 PharmaCyte Biotech Inc Company Overview
  • 5.28 Polytechnic University of Valencia Company Overview
  • 5.29 Rensselaer Polytechnic Institute Company Overview
  • 5.30 Senseonics Holdings Inc Company Overview
  • 5.31 Tandem Diabetes Care Inc Company Overview
  • 5.32 TecMed Inc Company Overview
  • 5.33 The Alfred Mann Foundation Company Overview
  • 5.34 TypeZero Technologies LLC Company Overview
  • 5.35 Universidad Autonoma de Madrid Company Overview
  • 5.36 University of California San Francisco Company Overview
  • 5.37 University of California Santa Barbara Company Overview
  • 5.38 University of Cambridge Company Overview
  • 5.39 University of Florida Company Overview
  • 5.40 University of Newcastle Company Overview
  • 5.41 XERIS Pharmaceuticals Inc Company Overview
  • 5.42 Yale University Company Overview

6 Artificial Pancreas - Recent Developments

  • 6.1 Jun 09, 2019: Tandem Diabetes Care reports positive results from two studies of the t:slim X2 Insulin Pump With Control-IQ Technology
  • 6.2 Jun 09, 2019: Insulet's Omnipod Horizon Hybrid Closed-Loop System improves Glycemic Control in patients as young as two years Old with Type 1 Diabetes
  • 6.3 Jun 08, 2019: Medtronic initiates pivotal trial for Bluetooth enabled MiniMed 780G Advanced Hybrid Closed Loop System Designed to Automate Correction Bolusing
  • 6.4 Jun 08, 2019: The iLet Bionic Pancreas Increased Time in Range for Adults with Type 1 Diabetes
  • 6.5 Jun 07, 2019: Beta Bionics reports positive data from iLet Bionic Pancreas' study
  • 6.6 Jun 07, 2019: Tandem Diabetes Care announces Conference Call Following Data Presentations at the ADA Scientific Sessions
  • 6.7 Jun 06, 2019: Beta Bionics and Zealand Pharma announce superior glycemic control in Phase 2 home-use clinical trial testing the iLet bionic pancreas using dasiglucagon
  • 6.8 Jun 04, 2019: Medtronic awarded $150M contract from Defense Logistics Agency
  • 6.9 May 28, 2019: MiniMed 670G System Real-World Data on 8 Million patient days shows 71 percent time in range across all age groups
  • 6.10 May 23, 2019: Beta Bionics starts clinical trial of iLet bionic pancreas
  • 6.11 May 23, 2019: Medtronic announces fiscal year and fourth quarter 2019 financial results
  • 6.12 May 15, 2019: Publication in "The Lancet Digital Health" of the positive results of the WP7 clinical trial with Diabeloop's integrated DBLG1 device in real life
  • 6.13 May 09, 2019: New study demonstrates safety and effectiveness of the MiniMed 640G System reducing hypoglycemia compared with insulin pump therapy without CGM in type 1 diabetes
  • 6.14 May 09, 2019: Xeris Pharmaceuticals announces first quarter 2019 financial results and highlights its pipeline
  • 6.15 May 02, 2019: Insulet celebrates new global headquarters and U.S. manufacturing facility in Acton, MA
  • 6.16 May 02, 2019: Insulet Reports First Quarter 2019 Revenue of $159.6 Million, an Increase of 29% Year-Over-Year

7 Appendix

  • 7.1 Methodology
  • 7.2 About GlobalData
  • 7.3 Contact Us
  • 7.4 Disclaimer

List of Tables

  • Table 1: Artificial Pancreas - Pipeline Products by Stage of Development
  • Table 2: Artificial Pancreas - Pipeline Products by Territory
  • Table 3: Artificial Pancreas - Pipeline Products by Regulatory Path
  • Table 4: Artificial Pancreas - Pi

List of Figures

  • Figure 1: Artificial Pancreas - Pipeline Products by Stage of Development
  • Figure 2: Artificial Pancreas - Pipeline Products by Territory
  • Figure 3: Artificial Pancreas - Pipeline Products by Regulatory Path
  • Figure 4: Artificial Pancreas
Back to Top